Health economic evaluations in reimbursement decision making in the Netherlands: Time to take it seriously?

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen

Volumn 108, Issue 7, 2014, Pages 383-389

  Franken, Margreet ^a   Koopmanschap, Marc ^a   Steenhoek, Adri ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Health economic evaluation; health technology assessment; pharmaceutical market; policy making; reimbursement; The Netherlands

Indexed keywords

COMPARATIVE STUDY; COST BENEFIT ANALYSIS; CULTURAL FACTOR; DRUG COST; ECONOMICS; FORECASTING; HEALTH INSURANCE; HUMAN; NETHERLANDS; ORGANIZATION; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; TRENDS;

COST-BENEFIT ANALYSIS; CROSS-CULTURAL COMPARISON; DECISION MAKING, ORGANIZATIONAL; DRUG COSTS; FORECASTING; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; NATIONAL HEALTH PROGRAMS; NETHERLANDS; QUALITY-ADJUSTED LIFE YEARS; REIMBURSEMENT MECHANISMS;

EID: 84908361002     PISSN: 18659217     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.zefq.2014.06.016     Document Type: Article

References (29)

1. M. Berg, T. van der Grinten, and N. Klazinga Technology assessment, priority setting, and appropriate care in Dutch health care Int J Technol Assess Health Care 20 1 2004 35 43
2. T. Hoomans, N. van der Roer, and J.L. Severens Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement [in Dutch: Kosteneffectiviteit van nieuwe geneesmiddelen: van belang bij geneesmiddelenvergoeding, maar voor verbetering vatbaar] Ned Tijdschr Geneeskd 154 A958 2010 1 9
3. F. Rutten, and J. van der Linden Integration of economic appraisal and health care policy in a health insurance system; The Dutch case Soc Sci Med 38 12 1994 1609 1614
4. W. Van Rossum Decision-making and medical technology assessment: Three Dutch cases Knowledge, Technology & Policy 4 1 1991 107 124
5. Dunning Committee Committee on Choices in Health Care: Choices in Health Care 1992 Ministry of Welfare, Health and Cultural Affairs Rijswijk
6. CVZ. Van zorg verzekerd: Informatie over het College voor zorgverzekeringen. 2009.
7. B.T.L.E. Couwenbergh, F.M. van der Meer, and S.E. Weghaus-Reus Management of the basic benefit package in practice part 3 [in Dutch: Pakketbeheer in de praktijk deel 3] 2013 College voor Zorgverzekeringen Diemen Report No.: 2013095825
8. G. Ligtenberg, P.C. Staal, and W. Goettsch Cost-effectiveness in health care [in Dutch: Kosteneffectiviteit in de zorg] 2013 College voor Zorgverzekeringen Diemen Report No.: 2013082521
9. A. Klink Medicines Policy October 8, 2009 [In Dutch: Geneesmiddelenbeleid 8 oktober 2009] 2009 Ministerie van Volksgezondheid, Welzijn en Sport Den Haag Report No.: GMT-2960544
10. J. Zwaap, C.G. Mastenbroek, and B. van der Holt Management of the basic benefit package in practice 2 [in Dutch: Pakketbeheer in Praktijk 2] 2009 College voor zorgverzekeringen Diemen Report No.: 29033174
11. R. Dupree, and P. Pasman Management of the basic benefit package for specialist drugs [in Dutch: Pakketbeheer specialistische geneesmiddelen] 2013 College voor Zorgverzekeringen Diemen Report No.: 2013077869
12. CVZ Guidelines for pharmacoeconomic evaluations, updated version [in Dutch: Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie] 2006 College voor zorgverzekeringen Diemen Report No.: 25001605
13. M.G. Franken, M. Le Polain, and I. Cleemput Similarities and differences between five European drug reimbursement systems International Journal of Technology Assessment in Health Care 28 4 2012 349 357
14. M. le Polain, M.G. Franken, and M.A. Koopmanschap Drug reimbursement systems: international comparison and policy recommendations 2010 Belgian Health Care Knowledge Centre (KCE) Brussels Report No.: KCE Reports 147C
15. C. van der Meijden Reimbursement procedure for outpatient drugs [in Dutch: Procedure beoordeling extramurale geneesmiddelen] 2012 College voor Zorgverzekeringen Diemen Report No.: 2010117719
16. E. Borst Changes in the attachments of the pharmaceutical benefit scheme [in dutch: Wijziging bijlagen regeling farmaceutische hulp 1996] Official gazette of the Dutch State 6 10 2000 Sect. April
17. M. Franken, F. Nilsson, and F. Sandmann Unravelling drug reimbursement outcomes: A comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision-making PharmacoEconomics [DOI 10.1007/s40273-013-0074-1] 31 9 2013 781 797
18. T. Hoomans, J.L. Severens, and N. van der Roer Methodological quality of economic evaluations of new pharmaceuticals in the Netherlands Pharmacoeconomics 30 3 2012 219 227
19. Rutte M, Samson D. Coalition report [in Dutch: Bruggen slaan: Regeerakkoord VVD-PvdA]. http://www.rijksoverheid.nl/regering/documenten-en-publicaties/rapporten/2012/10/29/regeerakkoord.html. 2012 29 October 2012.
20. College voor Zorgverzekeringen Pay-for-Performance agreement for omalizumab (Xolair) for treatment of severe asthma [in Dutch: Pay-for-Performance overeenkomst omalizumab (Xolair) voor de behandeling van ernstige astma]. http://www.cvz.nl/binaries/content/documents/zinl-www/documenten/publicaties/rapporten-en-standpunten/2012/1208-pay-for-performance-overeenkomst-omalizumab-xolair-voor-de-behandeling-van-ernstige-astma/1208-pay-for-performance-overeenkomst-omalizumab-xolai 2012 College voor Zorgverzekeringen Diemen Report No.: ZA/2012056679
21. P.J. Neumann, J.D. Chambers, and F. Simon Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement Health Aff 30 12 2011 2329 2337
22. C.L.M. Sudlow, and C.E. Counsell Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis BMJ 326 7385 2003 388 392
23. CVZ Farmacotherapeutisch rapport ipilimumab (Yervoy®) bij de indicatie 'inoperabel of gemetastaseerd melanoom in een gevorderd stadium bij volwassenen die al eerder behandeld zijn' ZA/2012010215 2012 CVZ Diemen
24. CVZ Advice regarding alglucosidase alfa (Myozyme ®) for the indication of alglucosidase alfa deficiency (Pompe disease) [in Dutch: Advies alglucosidase alfa (Myozyme ®) bij alglucosidase alfa deficientie (ziekte van Pompe)] 2012 College voor Zorgverzekeringen Diemen Report No.: ZA/2012134239
25. J. Kievit Orphan durgs, and Pompe and Fabry disease: health care policy with compassion as well as intellect [in Dutch: Weesgeneemiddelen, en de ziekten van Fabry en Pompe: over gezondheidszorgbeleid met compassie zowel als verstand]. Letter of ACP member 2012 College voor Zorgverzekeringen Diemen
26. Ministerial Point of view Pompe and Fabry [in Dutch: Standpunt Pompe En Fabry]. 155165-111008-GMT (Ministerial Letter, 2013).
27. Commissie BOM Systematic assessment of oncological treatments [in Dutch: Systematische beoordeling van oncologische middelen] Medische Oncologie 2012 1 2012 26 29
28. M.K. Kvamme, D. Gyrd-Hansen, and J.A. Olsen Increasing marginal utility of small increases in life-expectancy? Results from a population survey J Health Econ 29 4 2010 541 548
29. J. McKie, and J. Richardson The rule of rescue Soc Sci Med 56 12 2003 2407 2419